UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended April 3, 2005
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE NUMBER
1-3619
----
PFIZER
INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street,
New York, New York 10017
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X
NO
Indicate by check mark whether the registrant is an
accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
YES X
NO
At May 3, 2005, 7,435,344,024 shares of the
issuer's voting common stock were outstanding.
FORM
10-Q
For the
Quarter Ended
April 3, 2005
Table
of Contents
PART
I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements:
Condensed Consolidated
Statement of Income for the three months ended April 3, 2005 and March 28,
2004
Condensed Consolidated
Balance Sheet at April 3, 2005 and December 31, 2004
Condensed Consolidated
Statement of Cash Flows for the three months ended April 3, 2005 and March 28,
2004
Notes to Condensed
Consolidated Financial Statements
Review Report of Independent
Registered Public Accounting Firm
16
Item 2.
Management's Discussion
and Analysis of Financial Condition and Results of Operations
17
Item 4.
Controls and Procedures
37
PART
II. OTHER INFORMATION
Item 1.
Legal Proceedings
38
Item 2.
Unregistered Sales of
Equity Securities and Use of Proceeds
38
Item 4.
Submission of Matters
to a Vote of Security Holders
39
Item 6.
Exhibits
40
Signature
41
Certifications
44
PART
I. FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC AND SUBSIDIARY
COMPANIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(UNAUDITED)
Three Months
Ended
(millions of dollars, except per common share data)
April 3,
2005
March 28,
2004
Revenues
13,091
12,487
Costs and expenses:
Cost of sales(1)
2,191
1,794
Selling, informational
and administrative expenses(1)
4,085
3,933
Research and development
expenses(1)
1,764
1,649
Amortization of
intangible assets
882
823
Merger-related
in-process research and development charges
955
Merger-related costs
219
247
Other
(income)/deductions-net
1,038
(43)
Income from
continuing operations before provision for taxes on income, and minority
interests
2,910
3,129
Provision for taxes on
income
2,635
809
Minority interests
Income from
continuing operations
272
2,318
Discontinued operations:
Income/(loss) from discontinued
operations-net of tax
(12)
13
Gains on sales of
discontinued operations-net of tax
41
--
Discontinued
operations-net of tax
29
13
Net income
301
2,331
Earnings per common share - Basic:
Income from
continuing operations
.04
.31
Discontinued
operations-net of tax
--
--
Net income
.04
.31
Earnings per common share - Diluted:
Income from
continuing operations
.04
.30
Discontinued
operations-net of tax
--
--
Net income
.04
.30
Weighted-average shares
used to calculate earnings per common share:
Basic
7,416
7,586
Diluted
7,474
7,679
Cash dividends paid per common share
.19
.17
(1)
Exclusive of amortization of intangible assets,
except as disclosed in Note 9B, Goodwill
and Other Intangible Assets: Other Intangible Assets.
See accompanying Notes to
Condensed Consolidated Financial Statements.
PFIZER INC AND SUBSIDIARY
COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEET
(UNAUDITED)
(millions of dollars)
April 3,
2005*
Dec. 31,
2004**
ASSETS
Current Assets
Cash and cash
equivalents
1,476
1,808
Short-term investments
20,495
18,085
Accounts receivable,
less allowance for doubtful accounts: $214 and $205
10,074
9,367
Short-term loans
587
653
Inventories
6,551
6,660
Prepaid expenses and taxes
2,792
2,939
Assets held for sale
378
182
Total current assets
42,353
39,694
Long-term investments
and loans
3,619
3,873
Property, plant and
equipment, less accumulated depreciation: $8,682 and $8,534
17,912
18,385
Goodwill
23,671
23,756
Identifiable intangible
assets, less accumulated amortization
31,001
33,251
Other assets, deferred
taxes and deferred charges
4,379
4,725
Total assets
122,935
123,684
LIABILITIES AND
SHAREHOLDERS' EQUITY
Current Liabilities
Short-term borrowings,
including current portion of long-term debt: $1,390 and $907
13,399
11,266
Accounts payable
2,300
2,672
Dividends payable
1,418
Income taxes payable
5,288
1,963
Accrued compensation
and related items
1,601
1,939
Other current
liabilities
6,315
7,136
Liabilities held for
sale
42
64
Total current liabilities
28,948
26,458
Long-term debt
6,432
7,279
Pension benefit
obligations
2,897
2,821
Postretirement benefit
obligations
1,448
1,450
Deferred taxes on
income
12,737
12,632
Other noncurrent
liabilities
2,941
4,766
Total liabilities
55,403
55,406
Shareholders' Equity
Preferred stock
187
193
Common stock
438
438
Additional paid-in
capital
67,096
67,098
Retained earnings
35,785
35,492
Accumulated other
comprehensive income
1,909
2,278
Employee benefit trust,
at fair value
(1,002)
(1,229)
Treasury stock
(36,881)
(35,992)
Total shareholders' equity
67,532
68,278
Total liabilities and shareholders' equity
122,935
123,684
* Unaudited.
** Condensed from audited financial
statements.
See accompanying Notes to
Condensed Consolidated Financial Statements.
PFIZER INC AND SUBSIDIARY
COMPANIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)
Three Months
Ended
(millions of dollars)
April 3,
2005
March 28,
2004
Operating
Activities:
Net income
301
2,331
Adjustments to reconcile
net income to net cash provided by continuing operating activities:
Income from discontinued
operations
(29)
(13)
Depreciation and
amortization
1,366
1,261
Merger-related
in-process research and development charges
955
Asset impairment charge
and other costs associated with the suspension of Bextra sales
1,213
--
Deferred taxes
484
(284)
Other
96
174
Changes in assets and
liabilities (net of businesses acquired and divested)
(259)
(2,841)
Net cash provided by continuing operating activities
3,174
1,583
Investing Activities:
Purchases of property,
plant and equipment
(465)
(472)
Purchases of short-term
investments
(4,891)
(4,603)
Proceeds from
redemptions of short-term investments
2,550
2,613
Purchases of long-term
investments
(494)
(453)
Proceeds from sales of
long-term investments
437
816
Purchases of other
assets
(70)
(153)
Proceeds from sales of
other assets
--
109
Acquisition of
businesses, net of cash acquired
--
(1,443)
Proceeds from the sales
of businesses and product lines
93
--
Other investing
activities
154
(135)
Net cash used in investing activities
(2,686)
(3,721)
Financing Activities:
Increase in short-term borrowings,
net
1,591
1,776
Decrease in short-term borrowings,
net
(205)
(106)
Proceeds from issuances
of long-term debt
1,524
Principal payments on
long-term debt
(1)
(3)
Proceeds from common
stock issuances
20
17
Purchases of common
stock
(919)
(912)
Cash dividends paid
(1,400)
(1,282)
Stock option
transactions and other
95
569
Net cash (used in)/provided
by financing activities
(818)
1,583
Net cash provided by
discontinued operations
--
--
Effect of exchange-rate
changes on cash and cash equivalents
(2)
--
Net decrease in cash and
cash equivalents
(332)
(555)
Cash and cash
equivalents at beginning of period
1,808
1,520
Cash and cash
equivalents at end of period
1,476
965
Supplemental Cash
Flow Information:
Cash paid during the
period for:
Income taxes
557
796
Interest
141
69
See accompanying Notes to
Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1: Basis of Presentation
We prepared the condensed consolidated financial statements following
the requirements of the Securities and Exchange Commission (SEC) for interim
reporting. As permitted under those rules, certain footnotes or other financial
information that are normally required by accounting principles generally
accepted in the United States of America (GAAP) can be condensed or omitted.
Balance sheet amounts and operating results for subsidiaries operating outside
the U.S. are as of and for the three-month periods ended February 27, 2005 and February
22, 2004. The fiscal first quarter of 2005 had three additional business days
compared to the fiscal first quarter of 2004.
We are responsible for the unaudited financial statements included in
this document. The financial statements include all normal and recurring
adjustments that are considered necessary for the fair presentation of our
financial position and operating results.
Revenues, expenses, assets and liabilities can vary during each quarter
of the year. Therefore, the results and trends in these interim financial
statements may not be representative of those for the full year.
The information included in this Quarterly Report on Form 10-Q should
be read in conjunction with the consolidated financial statements and
accompanying notes included in Pfizer's Annual Report on Form 10-K for the
year ended December 31, 2004.
In accordance with Statement of Financial Accounting Standards (SFAS)
No. 123, Accounting for Stock-Based
Compensation, we elected to account for our stock-based compensation
under Accounting Principles Board Opinion (APB) No. 25, Accounting for Stock Issued to Employees.
The exercise price of stock options granted equals the market price on the date
of grant. There is no recorded expense related to grants of stock options.
The weighted-average fair
value per stock option granted was $5.15 for the three months ended April 3,
2005, and $6.88 for the three months ended March 28, 2004. We estimated the
fair values, as required under GAAP, using the Black-Scholes option-pricing
model, modified for dividends and using the assumptions below. In the first
quarter of 2005, we changed our method of estimating expected dividend yield
from historical patterns of dividend payments to a method that reflects a
constant dividend yield during the expected term of the option.
Three Months
Ended
April 3,
2005
March 28,
2004
Expected dividend yield
2.90%
2.90%
Risk-free interest rate
3.96%
3.32%
Expected stock price volatility
21.93%
22.15%
Expected term until exercise (years)
5.75
5.75
The following table
summarizes our results for the three-month periods ended April 3, 2005 and
March 28, 2004 as if we had recorded compensation expense for the option
grants:
Three Months
Ended
(millions of dollars, except per common share data)
April 3,
2005
March 28,
2004
Net income available to
common shareholders used in the calculation of basic earnings per common
share:
As reported under GAAP*
299
2,330
Compensation expense
(147)
(126)
Pro forma
152
2,204
Basic earnings per
common share:
As reported under GAAP*
.04
.31
Compensation expense
(.02)
(.02)
Pro forma
.02
.29
Net income available to
common shareholders used in the calculation of diluted earnings per common
share:
As reported under GAAP*
300
2,330
Compensation expense
(147)
(126)
Pro forma
153
2,204
Diluted earnings per
common share:
As reported under GAAP*
.04
.30
Compensation expense
(.02)
(.01)
Pro forma
.02
.29
Includes stock-based compensation expense, net of
related tax benefits of $15 million for the three months ended April 3,
2005 and $29 million for the three months ended March 28, 2004.
Net income available to common shareholders used in the calculation of
basic earnings per common share represents net income reduced by preferred
stock dividends-net of tax. Net income available to common shareholders used in
the calculation of diluted earnings per common share represents net income
reduced by the incremental allocation of shares to the Employee Stock Ownership
Plans (ESOPs) acquired as part of the Pharmacia acquisition.
Note 2: Asset Impairment Charge and Other Costs Associated with the Suspension
of Bextra Sales
In the first quarter of 2005, we recorded charges totaling
$1,213 million ($766 million net of tax) in connection with the decision
to suspend sales and marketing of Bextra.
On April 7, 2005, as
part of the U.S. Food and Drug Administration's (FDA) safety review of all COX-2
medicines, which began in late 2004 and included a mid-February 2005 meeting of
the FDA Arthritis Advisory Committee and the Drug Safety and Risk Management
Advisory Committee, the FDA requested the suspension of Bextra sales and
marketing.
The pre-tax charges
included $1,145 million related to the impairment of developed technology
rights associated with Bextra and $10 million related to the write-off of
machinery and equipment, both of which are included in Other income/(deductions)-net; $56 million
in write-offs of inventory, included in Cost
of sales; and $2 million related to the costs of administering
the suspension of sales, included in Selling,
informational and administrative expenses. In addition, we recorded
a net charge of $71 million, substantially against Revenues, for estimated customer returns.
Note 3: Income Taxes
In the first quarter of 2005, we recorded an income tax charge of
$2,189 million, included in Provisions
for taxes on income, in connection with our decision to repatriate
$28.3 billion of foreign earnings in accordance with the American Jobs Creation Act of 2004 (the
Act). This tax charge may be reduced by approximately $850 million in
future periods due to technical corrections legislation expected to be
considered in 2005.
The amount of foreign earnings to be repatriated pursuant to the Act
could be increased by up to $10.6 billion, subject to future guidance from
the U.S. Treasury. We expect the future guidance to clarify whether the unremitted
earnings of companies acquired after December 31, 2002 are eligible for
repatriation, as well as address the methodology under which unremitted
earnings are allocated among members of a group for financial statement
purposes which are not also part of the same consolidated tax group. Based on
information presently available, the income tax effects of such additional
repatriation could be up to $750 million.
As of April 3, 2005, we intend to continue to reinvest the earnings
of our international subsidiaries overseas and, therefore, we have not recorded
a U.S. tax provision on the remaining amount of unremitted earnings of our
international subsidiaries.
Note 4: Merger-Related
Costs
We incurred the following
merger-related costs primarily in connection with our acquisition of Pharmacia
Corporation (Pharmacia) which was completed on April 16, 2003:
Three Months
Ended
(millions of dollars)
April 3,
2005
March 28,
2004
Integration costs
106
104
Restructuring costs
113
143
Total merger-related
costs - expensed
219
247
In connection with the acquisition of Pharmacia, Pfizer management has approved
plans to restructure and integrate the operations of both legacy Pfizer and
legacy Pharmacia to combine operations, eliminate duplicative facilities and
reduce costs. The restructuring of our operations as a result of our
acquisition of Pharmacia is expected to continue through 2005 and is expected
to include consulting, systems integrations, severance, costs of vacating
duplicative facilities, contract termination and other exit costs.
Total merger-related expenditures expected to be incurred during 2003-2005
to achieve anticipated synergies are about $6.0 billion, on a pre-tax
basis. The remaining costs expected to be incurred are primarily associated
with asset impairments, exit costs and employee terminations.
Restructuring Costs
Through April 15,
2004, we recorded restructuring costs associated with employee terminations and
exiting certain activities of legacy Pharmacia. These costs were recognized as
liabilities assumed in the purchase business combination. Accordingly, the
restructuring costs incurred in the first year after the acquisition were
considered part of the purchase price of Pharmacia and were recorded as an
increase to goodwill. These restructuring costs also included costs associated
with relocation. Changes to previous estimates of restructuring costs included
as part of the purchase allocation of Pharmacia are recorded as a reduction to
goodwill or an expense to operations, as appropriate. Restructuring costs
incurred for legacy Pfizer and restructuring costs incurred after
April 15, 2004 for legacy Pharmacia are charged to the results of
operations.
The components of restructuring
costs follow:
(millions of dollars)
Total
Utilization
Through
April 3,
2005
(a)
Reserve*
April 3,
2005
Costs capitalized through April 15, 2004:
Employee termination
costs
1,535
1,484
51
Other
624
482
142
2,159
1,966
193
Costs expensed:
Employee termination
costs
569
431
138
Asset impairments
341
341
--
Other
84
45
39
994
817
177
Included in Other
current liabilities.
(a)
Includes insignificant adjustments to original
amounts established.
During the first quarter of 2005, we expensed $52 million for Employee termination costs, $51 million
for Asset impairments and $10 million
in Other. Through April 3, 2005, Employee termination costs represent the
approved reduction of the legacy Pfizer and legacy Pharmacia work force by
16,937 employees, mainly in corporate, manufacturing, distribution, sales
and research. We notified affected individuals and 15,676 employees were
terminated as of April 3, 2005. Employee
termination costs include accrued severance benefits and costs
associated with change-in-control provisions of certain Pharmacia employment
contracts. Asset impairments primarily
include charges to write-down property, plant and equipment. Other primarily includes costs to exit